Intellipharmaceutics International, Inc. (IPCIQ)
0.0000
0.00 (0.00%)
USD |
OTCM |
Dec 09, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 0.00 |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 0.00% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 100.00% |
Profile
| Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a controlled-release drug delivery platform that can be applied to the development of pharmaceuticals in the areas of neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company was founded by Isa Odidi and Amina Odidi in 1998 and is headquartered in Toronto, Canada. |
| URL | http://www.intellipharmaceutics.com |
| Investor Relations URL | http://www.intellipharmaceutics.com/investor_relations.cfm |
| HQ State/Province | Ontario |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | N/A |
| Last Earnings Release | Oct. 14, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a controlled-release drug delivery platform that can be applied to the development of pharmaceuticals in the areas of neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company was founded by Isa Odidi and Amina Odidi in 1998 and is headquartered in Toronto, Canada. |
| URL | http://www.intellipharmaceutics.com |
| Investor Relations URL | http://www.intellipharmaceutics.com/investor_relations.cfm |
| HQ State/Province | Ontario |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | N/A |
| Last Earnings Release | Oct. 14, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |